Testosterone MD-Lotion Residual Washing Study

Acrux DDS Pty Ltd10 enrolled

Overview

The study will evaluate the amount of Testosteron MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Hypergonadism

Interventions

Testosterone MD-LotionDRUG

Single dose Testosterone MD-Lotion 2%

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male subjects ≥18 and ≤ 70 years Exclusion Criteria: * Disqualifying concurrent condition or allergy/sensitivity to Testosterone MD-Lotion

Locations (1)

QPharm Pty Ltd

Brisbane, Queensland, Australia

Outcomes

Primary Outcomes

The amount of Testerone MD-Lotion 2% remaining on the axilla after a single dose application in healthy males who undergo a post dose washing procedure.

Time frame: March 2010

Secondary Outcomes

The safety and tolerability of Testosterone MD-Lotion 2% following a single dose application. This will be performed by review of adverse events, EKG and assessment of laboratory parameters (haematology, biochemistry, urinalysis and hormone levels).

Time frame: March 2010

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.